These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 12759615

  • 1. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO, U.S. Preventive Services Task Force.
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract] [Full Text] [Related]

  • 2. Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
    Harv Womens Health Watch; 2002 Oct; 10(2):1-2. PubMed ID: 12393316
    [No Abstract] [Full Text] [Related]

  • 3. [Additional effect of SERM: mammary gland].
    Kurebayashi J.
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bone builder vs. breast cancer.
    Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491
    [No Abstract] [Full Text] [Related]

  • 6. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar 15; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract] [Full Text] [Related]

  • 7. Drugs can reduce the incidence of breast cancer: now what?
    Wozniak TF, Eppes PG, Wilson CT.
    Del Med J; 1999 Sep 15; 71(9):387-9. PubMed ID: 10584440
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Raloxifene works as well as tamoxifen in preventing invasive breast cancer.
    Mayo Clin Womens Healthsource; 2006 Oct 15; 10(10):3. PubMed ID: 16977270
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC.
    Eur J Cancer; 2006 Nov 15; 42(17):2909-13. PubMed ID: 17064889
    [Abstract] [Full Text] [Related]

  • 12. Breast cancer risk management.
    Reeder JG, Vogel VG.
    Clin Breast Cancer; 2007 Dec 15; 7(11):833-40. PubMed ID: 18269772
    [Abstract] [Full Text] [Related]

  • 13. Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
    Runowicz CD.
    Health News; 2003 Apr 15; 9(4):1-2. PubMed ID: 12710388
    [No Abstract] [Full Text] [Related]

  • 14. The current status of breast cancer chemoprevention: a star is born.
    Morrow M, Jordan VC.
    J Surg Oncol; 2007 Jan 01; 95(1):4-5. PubMed ID: 17192883
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chemoprevention of breast cancer.
    O'Regan RM.
    Cancer Treat Res; 2000 Jan 01; 103():183-207. PubMed ID: 10948447
    [No Abstract] [Full Text] [Related]

  • 17. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.
    Jordan VC.
    Cancer Epidemiol Biomarkers Prev; 2007 Nov 01; 16(11):2207-9. PubMed ID: 18006908
    [No Abstract] [Full Text] [Related]

  • 18. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May 08; 48(1234):37. PubMed ID: 16685245
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.